Breaking News Instant updates and real-time market news.

AMGN

Amgen

$189.44

-0.26 (-0.14%)

06:10
09/15/17
09/15
06:10
09/15/17
06:10

Amgen: FOURIER analysis shows Repatha reduces cardiovascular events

Amgen announced that a new analysis of the cardiovascular outcomes study, or FOURIER, demonstrated that lowering low-density lipoprotein cholesterol, or LDL-C, levels with Repatha significantly and consistently reduced cardiovascular events in patients with and without diabetes at baseline. The analysis showed that diabetes was independently associated with a substantially increased risk of cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease. Patients with diabetes tended to have a greater absolute risk reduction of cardiovascular events with Repatha treatment because of their heightened baseline risk. Consistent with recent trials of more intensive LDL lowering, Repatha has not shown an effect on cardiovascular mortality.1-5 The analysis also showed that Repatha was not associated with an increased risk of new-onset diabetes or worsening glycemia over a median of 2.2 years of follow-up in patients without diabetes or pre-diabetes. Additionally, no new safety concerns were identified in this analysis. The results were presented today at the 53rd Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal and simultaneously published in The Lancet Diabetes & Endocrinology.

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

AMGN Amgen
$189.44

-0.26 (-0.14%)

09/14/17
RBCM
09/14/17
INITIATION
Target $192
RBCM
Sector Perform
Amgen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Amgen with a Sector Perform and an $192 price target.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $193
PIPR
Overweight
Amgen still has long way to go in asthma, says Piper Jaffray
After last night's Phase 2 trial data of Amgen's (AMGN) tezepelumab in severe asthma, Piper Jaffray analyst Christopher Raymond says the drug "looks to be in the ballpark but still numerically short of the mark" when compared with Regeneron's (REGN) Dupixent's Phase 2 profile. He thinks full Phase 3 data will be the ultimate determinant of the relative merits of each mechanism and reminds investors that such data have not been seen for either drug. In a research note titled, "Tezepelumab Phase 2 Asthma Data Gets Amgen in the Game, But Still a Long Way to Go," James keeps an Overweight rating on Amgen, while noting tezepelumab, with Phase 3 data likely a few years out, is not in his valuation model.
09/07/17
SBSH
09/07/17
NO CHANGE
Target $575
SBSH
Buy
Regeneron asthma treatment still looks better than Amgen's, says Citi
Citi analyst Robyn Karnauskas says that while Amgen's (AMGN) and AstraZeneca's (AZN) asthma data is encouraging, Regeneron's (REGN) dupilumab appears to have better lung function profile in cross trial comparison. On a key endpoint of lung function improvement, Amgen's Tezepelumab does not appear to be providing a lot of benefit, Karnauskas tells investors in a research note. She notes that dupilumab in its phase 3 trial showed 12% improvement on lung function. Regeneron's asthma drug "is ahead and potentially better," Karnauskas writes. She keeps a Buy rating on Regeneron with a $575 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

13:17
09/19/17
09/19
13:17
09/19/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/19/17
09/19
13:16
09/19/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

$76.15

-1.53 (-1.97%)

13:15
09/19/17
09/19
13:15
09/19/17
13:15
Options
HCA Holdings put volume heavy and directionally bearish »

Bearish flow noted in HCA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/19/17
09/19
13:15
09/19/17
13:15
General news
Fed Policy Outlook: FOMC began its 2-day meeting »

Fed Policy Outlook: FOMC…

ICPT

Intercept

$95.75

0.87 (0.92%)

13:11
09/19/17
09/19
13:11
09/19/17
13:11
Conference/Events
Intercept management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WHR

Whirlpool

$170.86

0.02 (0.01%)

13:10
09/19/17
09/19
13:10
09/19/17
13:10
Hot Stocks
Whirlpool ticks lower after August appliance data »

Shares of Whirlpool moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$90.95

1.98 (2.23%)

13:05
09/19/17
09/19
13:05
09/19/17
13:05
Options
Tiffany call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

13:00
09/19/17
09/19
13:00
09/19/17
13:00
General news
FOMC forecast revisions »

FOMC forecast revisions…

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:58
09/19/17
09/19
12:58
09/19/17
12:58
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

KR

Kroger

$21.29

-0.1501 (-0.70%)

12:55
09/19/17
09/19
12:55
09/19/17
12:55
Options
Kroger put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:51
09/19/17
09/19
12:51
09/19/17
12:51
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

FCAU

Fiat Chrysler

$17.10

0.275 (1.64%)

12:49
09/19/17
09/19
12:49
09/19/17
12:49
Hot Stocks
FCA US recalling 443,712 U.S.-market heavy-duty pickups, medium-duty trucks »

FCA US LLC is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$75.16

-0.15 (-0.20%)

12:48
09/19/17
09/19
12:48
09/19/17
12:48
Hot Stocks
Microsoft Azure IP Advantage available in China on October 1 »

Microsoft said on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

AA

Alcoa

$45.77

0.86 (1.91%)

12:45
09/19/17
09/19
12:45
09/19/17
12:45
Options
Alcoa call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$4.15

-0.25 (-5.68%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Conference/Events
Noodles & Company management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Schneiderman, coalition of AGs expand multistate probe into opioid crisis »

New York Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.48

-3.06 (-1.38%)

ABC

AmerisourceBergen

$80.24

-0.43 (-0.53%)

CAH

Cardinal Health

$66.37

-0.7 (-1.04%)

MCK

McKesson

$150.02

1.6 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Lexicon announces European Commission approves Xermelo »

Lexicon Pharmaceuticals…

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:35
09/19/17
09/19
12:35
09/19/17
12:35
General news
Today's U.S. reports »

Today's U.S. reports…

LEG

Leggett & Platt

$45.25

-0.635 (-1.38%)

12:34
09/19/17
09/19
12:34
09/19/17
12:34
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, VIA

Viacom

$37.45

-0.4 (-1.06%)

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Periodicals
Viacom leak may have compromised digital properties, Gizmodo reports »

A security researcher…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

VIA

Viacom

$37.45

-0.4 (-1.06%)

VIAB

Viacom

$27.32

-0.35 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACTG

Acacia Research

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Hot Stocks
Acacia Research shares trade higher amid insider buying »

A number of insiders at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$48.82

0.79 (1.64%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Conference/Events
Green Dot management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$155.77

1.28 (0.83%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Options
Adobe attracts a pre-earnings call writer »

Adobe attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28
Hot Stocks
Michigan AG says 41 state attorneys general now involved in opioid probe »

Michigan Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

EFX

Equifax

$94.55

0.17 (0.18%)

12:27
09/19/17
09/19
12:27
09/19/17
12:27
Periodicals
Massachusetts Attorney General files lawsuit against Equifax, Reuters reports »

The State of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.